Novo Cuts Forecast After Weight-Loss Drug Sales Fall Short

Novo Nordisk A/S has significantly lowered its 2024 financial forecast, now projecting sales growth of 8-14% and operating profit growth of 10-16% at constant exchange rates, a sharp reduction from previous estimates of up to 21% and 24% respectively. This downward revision is primarily due to weaker-than-anticipated sales of its weight-loss drug Wegovy, signaling a loss of market share to competitor Eli Lilly & Co. in the burgeoning obesity treatment market and leading to a sharp decline in Novo Nordisk's shares.

Analysis

Novo Nordisk A/S has issued an unscheduled and significant downward revision to its full-year financial guidance, signaling material weakness in its commercial operations. The company now projects sales growth of 8% to 14% and operating profit growth of 10% to 16% at constant exchange rates, a stark reduction from its previous forecasts of up to 21% and 24%, respectively. This guidance cut is directly attributed to underperforming sales of its key weight-loss drug, Wegovy. The development indicates that Novo Nordisk is losing market share to its primary competitor, Eli Lilly & Co., in the highly lucrative obesity treatment market, a conclusion supported by the market's immediate and severe negative reaction, with shares plunging post-announcement. The situation highlights the intensifying competitive pressures and challenges Novo's previously assumed dominance in this therapeutic area.

Key Decisions for Investors

• Investors should reassess their thesis for Novo Nordisk, as the significant guidance cut and Wegovy's sales shortfall suggest its growth trajectory is moderating due to intense competition.
• The development serves as a strong positive signal for Eli Lilly & Co., indicating it is successfully capturing market share and strengthening its competitive position in the obesity market.
• Monitor comparative sales data for Wegovy and competing drugs from Eli Lilly, as market share shifts have now become the primary performance driver and risk factor for both companies.